What's Happening?
Turn Therapeutics, a biotechnology company, is set to present its lead investigational therapy, GX-03, at the Jefferies Global Healthcare Conference in New York City. The presentation will be delivered by CEO Bradley Burnam on June 4, 2026. GX-03 is a first-in-class,
non-systemic topical inhibitor designed to treat moderate-to-severe atopic dermatitis by targeting inflammatory pathways involving cytokines IL-36 and IL-31. The therapy is currently in a Phase 2 trial, with results expected in mid-2026. The company focuses on precision therapies for inflammatory diseases with high unmet needs.
Why It's Important?
The development of GX-03 represents a significant advancement in the treatment of atopic dermatitis, a condition affecting millions. By targeting specific cytokines involved in inflammation and the itch-scratch cycle, GX-03 could offer a new, non-systemic treatment option, potentially reducing the need for systemic therapies that often come with more side effects. This innovation could benefit patients with limited treatment options and improve quality of life. The presentation at a major healthcare conference highlights the therapy's potential impact and the company's commitment to addressing unmet medical needs.
What's Next?
Following the presentation, Turn Therapeutics will continue its Phase 2 trial of GX-03, with topline results anticipated in mid-2026. The outcome of this trial will be crucial in determining the next steps for the therapy's development, including potential progression to Phase 3 trials. The company may also seek partnerships or additional funding to support further research and development. Stakeholders, including investors and healthcare professionals, will be closely monitoring the trial results and subsequent developments.
